Segments - Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market by Types of Cancers (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Products (Therapeutics [ Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and Others] and Diagnostics [Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, and CT Scan], and Geographies (GCC, South Africa, and Rest of Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The Middle East & Africa uterine cancer therapeutics & diagnostics market was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 5.7% during 2023–2031. The growth of the market is attributed to rising awareness about uterine disease and increasing number of therapies for the same.
Uterine cancer is also known as womb cancer. Endometrial cancer and uterine sarcoma are two types of cancer that develops from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus and uterine sarcoma forms from the muscles or support tissue of the uterus. Symptoms of endometrial cancer is unusual vaginal bleeding or pelvis pain, while uterine sarcoma symptoms include vaginal bleeding or a lump in the vagina.
The cancer association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer. The mission aims to provide research grants, educating public regarding symptoms, screening and risk reduction, and providing care and support to patients affected by cancer. The department of health in South Africa implemented programs to improve the health of women. Thus, such programs are anticipated to increase early diagnosis procedures.
Increasing healthcare expenditure in drug development is expected to drive the market growth.
Ongoing technological advancements in medical devices is anticipated to positively impact the market growth.
Increasing obesity among women in the region can market growth.
Adverse effect of the treatment and high toxicity of drugs can hinder the market.
Rising innovation in drug development process is expected to create lucrative opportunities for industry players in the projected timeline.
The report on the Middle East & Africa uterine cancer therapeutics & diagnostics market research report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Types of Cancers (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Product (Therapeutics [Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and others] and Diagnostics [Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, and CT Scan] |
Regional Scope |
GCC, South Africa, and Rest of Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd |
Based on types of cancers, the market is divided into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. The endometrial adenocarcinoma segment is anticipated to account for a considerable market share during the forecast period. Increasing obesity in women is a primary factor responsible for the growing incidence of the endometrium carcinoma. Moreover, rising awareness about the cancer is excepted to drive the growth of the market segment. Endometrial cancer produces symptoms at early stages, which in turn, helps the patients to diagnose the cancer at early stage.
Based on products, the market is segregated into therapeutics and diagnostics. The therapeutics segment is further segmented into surgery, immunotherapy, radiation therapy, chemotherapy, and others. The diagnostic segment is classified as biopsy, pelvic ultrasound, hysteroscopy, dilation and curettage, and CT Scan. The chemotherapy segment is expected to hold a major market share owing to the lesser number of drugs approved for the treatment of endometrial cancer. This segment is expected to boost due to the high adoption rate of chemotherapy as compared to radiation and surgical treatment. The chemotherapeutic agents such as carboplatin and paclitaxel are recommended as the first line of therapy in the majority of the cancer cases, which is propelling the demand for these drugs.
In terms of geographies, the market is categorized as GCC, South Africa, and Rest of Middle East & Africa. The market in South Africa is anticipated to exhibit a high CAGR during the forecast period. Increasing prevalence of endometrial cancer, rising awareness about the early diagnosis of cancer, and the presence of the developed healthcare infrastructure are some of the key factors propelling the market growth in the country.
The Middle East & Africa uterine cancer therapeutics & diagnostics market has been segmented on the basis of
Key players operating in the Middle East & Africa uterine cancer therapeutics & diagnostics market includes Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd.